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Determination of the Number of Molecules Involved in Different Types of
Amphotericin B Channels
Javier In˜iguez-Stahl, Javier Gonza´lez-Damia´n, Iva´n Ortega-Blake.
Universidad Nacional Auto´noma de Me´xico, Cuernavaca, Mexico.
Electrophysiological properties of Amphotericin B (AmB) pores in lipid bi-
layers have been studied extensively with the purpose of understanding mem-
brane transport phenomena1. Also because AmB has a clinical relevance, it is
the drug of choice for treating systemic fungal infection in spite of having
strong collateral toxicity. One of the interests has been to determine the num-
ber of molecules involved in the formation of the ion channels reported.
Reports in the literature present values that go from 4 to 12. This has been
explained because channels with different conductivities are formed2 and
therefore the determination with macroscopic currents corresponds to an av-
erage of the population of different channels. In this work, we determined the
number of molecules of AmB involved in the formation of each one of these
pores by single channel methods3. Our results show that different types of
channels are formed by the same number of AmB molecules, which is
very interesting, considering that these channels have certainly different ra-
dius. This suggests a model in which AmB pores are not the only component
of the pores, having either lipids in a toroidal structure or sterols in a barrel
structure.
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Double Packaged System for Localized Drug Delivery for Ovarian
Cancer
Eva Christabel Williams, Ryan Toomey, Norma Alcantar.
University of South Florida, Tampa, FL, USA.
This research aims at developing a drug delivery system that will provide
a plethora of benefits such as cost effectiveness, reduction of toxicity and
a control over the release of chemotherapeutic drugs in Ovarian Cancer
patients. We have designed a model drug delivery system consisting of
non-ionic surfactant vesicles (niosomes) packaged within a biodegradable,
temperature and pH sensitive hydrogel (chitosan) network. Optimization of
the release rates were accomplished by altering the condition of its two com-
ponents, chitosan and niosome. Two ovarian cancer drugs Paclitaxel and
Carboplatin were used for encapsulation. It was found that medium
molecular weight chitosan with a crosslinker:chitosan ratio of 4:1 which cor-
responded to a pH of 7.4 resulted in the finest controlled release. Surface
characteristics, such as the interaction between the niosomes and chitosan
were determined using Surface Forces Apparatus. The system was also
tested in-vivo in mice models. Xenogen was used to study the release of
drugs in-vivo. Our results will help in the development of a low cost and
improved method for drug delivery with application to intracavitary ovarian
cancer treatment and other cancer types.
2607-Pos
Acid-Activation, Proton Transport Rate Saturation, and pH-Dependence
of Amantadine Block for Influenza a M2 Protein Truncate (22-62)
Emily Peterson1, Myunggi Yi2, Huan-Xiang Zhou2, Mukesh Sharma2,
Timothy A. Cross2, David Busath1.
1Brigham Young University, Provo, UT, USA, 2Florida State University,
Tallahassee, FL, USA.
A novel truncate (residues 22-62) of the influenza A M2 protein was tested
with pH-sensitive proteoliposome proton uptake assays. At six different
pHs, from 6.5 to 3.8, the proton flux into M2-containing liposomes (0.1
mg protein: 20 mg E. coli polar lipid:1 mL) increased to a maximum at
pH 4.9, and then decreased at the lowest measured pH levels. The lack
of proportionality to [Hþ] and saturation of flux indicate protein activity
consistent with transporter function, rather than a traditional ion "channel."
To gain mechanistic insight, the transport data are analyzed within a kinetic
model in which the four His34 residues are obligatory binding sites for
transported protons, and related to some results from molecular dynamicssimulations. Application of the antiviral drug amantadine (0.1 mM) to
the assay blocked ~80% of the M2 function at pH 6.5, as expected
when compared to published block efficiency in other, similar systems.
However, amantadine block became less effective as the pH of the assay
dropped, in keeping with observations by others from analytical centrifuga-
tion and Xenopus oocyte transport studies.2608-Pos
Can Passive Asymmetric Vacant Carrier Distributions Counterbalance
Asymmetric Carrier Affinities?
Richard J. Naftalin.
King’s College London, London, United Kingdom.
There is a popular fallacy that asymmetric vacant carrier distributions account
for asymmetric transporter affinities, e.g. GLUT1 and SGLT1. An alternating
site transporter can be passively asymmetrically distributed, because of differ-
ences in standard free energy, m’c, or activity coefficients, gc of the vacant
carrier isoforms, ci between the opposing membrane sides; i.e. either m’c
in <
m’c
out or gc
in < gc
out. Thus, at equilibrium the Gibbs free energy difference,
DGc of the vacant carrier distribution, DGc ¼ Dmc’ þ RTLn(ccout/ccin) ¼ 0.
Alternatively, if only the activity coefficients are unequal, DGc ¼
RTLn((cc
out.gc
out ) /(cc
in.gc
in)) ¼ 0. In both cases, at equilibrium, when
DGc ¼ 0, ccout < ccin.The carrier partition coefficient between the inside and
outside membrane phases Pin/out ¼ ccin/ccout hence Dm’cout-in ¼ - RTLn(Pin/out)
and DGc ¼ RTLn(ccout/(Pin/out..ccin)) ¼ 0 Since at equilibrium, unidirectional
vacant carrier flows kij.c
i are equal, kout-in.cc
out ¼ kin-out.ccin , hence ccin/ccout ¼
kout-in/kin-out ¼ Pin/out The flux ratio equation, DGc ¼ RTLN(kout-in/kin-out) ,
applicable to reactions in homogeneous membrane phases, requires a correc-
tion for asymmetric carrier equilibration between heterogeneous membrane
phases, becoming: DGc ¼ RTLn(kout-in/(Pin/out.kin-out) ¼ 0, or DGc ¼
RTLn(gc
out.kout-in/(gc
in.kin-out) ¼ 0. However, when these corrections are
applied, neither the asymmetric flux ratios, nor vacant carrier distributions
compensate for the energetic difference existing from the asymmetric ligand
affinities, i.e. if KD
out < KD
in then DGc
affinities ¼ RTLn(KDout/KDin) < 0. Since
a passively acquired asymmetric distribution at equilibrium generates no force,
no energy is available from the vacant carrier distribution to counterbalance
any energy difference between the asymmetric ligand affinities. Therefore,
asymmetric transport needs another rationalization.2609-Pos
Characterization of Mutant hCTR1 Copper Transporters Truncated by
Proteolytic Cleavage in the Absence of O-Linked Glycosylation at Thr27
Ed B. Maryon, Jack H. Kaplan.
Univ. of Illinois at Chicago, Chicago, IL, USA.
The human copper transporter hCTR1 is a plasma membrane protein of 190
amino acids that contains three transmembrane segments. Three hCTR1 poly-
peptides form symmetrical homotrimeric complexes that contain a permeation
pathway for copper transport across the plasma membrane that is formed by the
transmembrane segments (1). Little is known about the role(s) of the 65 amino
acid extracellular amino terminus.
In previous studies (2-4) we showed that extracellular terminus of hCTR1 con-
tains both N-linked (at Asn15) and O-linked (at Thr27) sites of glycosylation. If
O-glycosylation at Thr27 is prevented by mutation or by expressing wild type
hCTR1 in mutant cells that cannot initiate O-glycosylation, hCTR1 is effi-
ciently cleaved, removing 31-32 amino acids from the amino-terminus. The
cleaved amino terminal peptide accumulates in punctate structures in the cyto-
plasm that overlap compartments containing Rab9, indicating that hCTR1
cleavage occurs in a late golgi or late endosomal compartment. The amino-ter-
minal truncated hCTR1 transporters are delivered to the plasma membrane,
where they exhibit about 50% of the 64Cu uptake of full-length (wild type)
hCTR1 transporters.
We have further examined the truncated hCTR1 transporters for defects in cop-
per transport and copper-stimulated endocytosis, and we have characterized
wild type and amino terminal truncated hCTR1 transporter complexes in native
gels. The truncated transporters retain some copper regulatory and transport
characteristics, such as copper-stimulated endocytosis. Analysis of full-length
and amino-terminal truncated complexes in native gels indicates that the trun-
cated hCTR1 transporters may lack non-hCTR1 components present in wild
type hCTR1 complexes.
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